Phase 2 Light Clinical Trials
15 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–15 of 15 trials
Recruiting
Phase 1Phase 2
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion
Immunoglobulin Light Chain (AL) Amyloidosis
AbbVie76 enrolled23 locationsNCT06158854
Recruiting
Phase 2
CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Severe Renal Impairment
Multiple Myeloma (MM)Multiple Myeloma Light Chain Induced Renal Insufficiency
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT07585760
Recruiting
Phase 1Phase 2
Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients
Systemic Light Chain Amyloidosis
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.70 enrolled27 locationsNCT07266116
Recruiting
Phase 1Phase 2
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Relapsed/Refractory Systemic Light Chain Amyloidosis
Regeneron Pharmaceuticals220 enrolled19 locationsNCT06292780
Recruiting
Phase 1Phase 2
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
AmyloidosisLight Chain AmyloidosisRelapsed AL Amyloidosis+1 more
Alexion Pharmaceuticals, Inc.91 enrolled18 locationsNCT07081646
Recruiting
Phase 2
BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis
Systemic Light Chain Amyloidosis
Institute of Hematology & Blood Diseases Hospital, China21 enrolled1 locationNCT07151690
Recruiting
Phase 2
3-Month Clinical Trial of Liquid S-PRF in Periodontal Debridement for Periodontitis Stages II-IV
Periodontitis Chronic Generalized ModeratePeriodontitisPeriodontitis (Stage 3)+6 more
Mahsa University14 enrolled1 locationNCT07293962
Recruiting
Phase 2
Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis
Primary Light-Chain Amyloidosis
Keymed Biosciences Co.Ltd90 enrolled2 locationsNCT07039578
Recruiting
Phase 2
Teclistamab-Daratumumab in AL Amyloidosis
Amyloid Light-chain Amyloidosis
Suzanne Lentzsch, MD25 enrolled1 locationNCT07110844
Recruiting
Phase 1Phase 2
Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis
Light Chain (AL) Amyloidosis
Nexcella Inc.40 enrolled18 locationsNCT06097832
Recruiting
Phase 2
Daratumumab Combined With Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14)
Light Chain (AL) Amyloidosis
Peking Union Medical College Hospital36 enrolled1 locationNCT06629818
Recruiting
Phase 2
Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis
Multiple Myeloma, Refractory to Standard TreatmentMultiple Myeloma, RelapsedLight Chain Amyloidosis
Polina Stepensky180 enrolled1 locationNCT06971380
Recruiting
Phase 2
Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance
Motion Sickness, SpaceMotion SimulationParabolic Flight
Repurposed Therapeutics, Inc.80 enrolled1 locationNCT05852730
Active
Phase 2
The efficacy of Isatuximab plus Pomalidomine and Dexamethasone in patients with amyloid light-chain (AL) amyloidosis who have not responded to previous therapy
Amyloid light chain (AL) Amyloidosis
Intergroupe francophone du myelome16 enrolled1 locationACTRN12621001530819
Recruiting
Phase 2
A Double-Blind, Randomised, Single Centre, Placebo-Controlled Phase II Study to Evaluate the Safety and Efficacy of a Single Subcutaneous Implant of EPT 1647 in Patients Suffering from Recurrent Polymorphous Light Eruption
Polymorphous Light Eruption (PMLE)
Epitan Limited30 enrolled1 locationACTRN12605000369628